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Abstract
Background Chronic hepatitis C virus (HCV) infection
with genotypes (GT) 1 and 2 accounts for over 50% of
HCV infections globally, including over 97% of all HCV
infections in Japan. Here, we report an integrated analysis
of efficacy and safety of 8-week treatment with the all-oral,
fixed-dose combination of the direct acting antivirals
(DAA), glecaprevir and pibrentasvir (G/P), in DAA-naı¨ve
Japanese and overseas patients without cirrhosis and with
HCV GT1 or GT2 infection.
Methods Data from 899 DAA-naı¨ve patients without cir-
rhosis and with HCV GT1 or GT2 infection treated with
G/P (300/120 mg) for 8 weeks in the six Phase 2 or 3
overseas or Japan-only clinical trials were included. All
patients who received C 1 dose of G/P were included in an
intent-to-treat (ITT) analysis. The objectives were to
evaluate rate of sustained virologic response 12 weeks
post-treatment (SVR12) and safety of the 8-week regimen
in the ITT population.
Results Overall, SVR12 was achieved by 98.9% (889/899)
of DAA-naı¨ve patients without cirrhosis, including 99.2%
(597/602) of GT1-infected and 98.3% (292/297) of GT2-
infected patients. Less than 1% (2/899) of patients overall
and no Japanese patients experienced virologic failure.
SVR12 rate was[ 97% for patients regardless of baseline
characteristics, and common comorbidities or co-medica-
tions. Overall, \ 1% (2/899) discontinued G/P due to an
adverse event (AE) and 1.6% (14/899) of patients experi-
enced a serious AE.
Conclusions 8-week G/P treatment is safe and efficacious
in DAA-naive patients without cirrhosis and with HCV
GT1 or GT2 infection, demonstrating high SVR12 rates
regardless of baseline patient and disease characteristics.
ClinicalTrials.gov identifiers The trials discussed in this
paper were registered with ClinicalTrials.gov as follows:
NCT02707952 (CERTAIN-1), NCT02723084 (CERTAIN-
2), NCT02243280 (SURVEYOR-I), NCT02243293
(SURVEYOR-II), NCT02604017 (ENDURANCE-1),
NCT02738138 (EXPEDITION-2).
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response
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Table 1 Baseline demographics and disease characteristics
Characteristic GT1
N = 602
GT2
N = 297
Overall
N = 899
Male, n (%) 304 (50) 141 (47) 445 (49)
Race, n (%)
White 384 (64) 171 (59) 555 (62)
Black or African American 33 (5) 13 (4) 46 (5)
Asiana 180 (30) 107 (36) 287 (31)
Other 5 (\ 1) 6 (2) 11 (1)
Age, median (range), years 54 (19–86) 57 (21–83) 55 (19–86)
Age distribution, n (%)
C 65 113 (19) 61 (21) 174 (19)
C 75 31 (5) 13 (4) 44 (5)
BMI, median (range), kg/m2 24.7 (16.2–41.4) 25.3 (14.2–65.7) 24.8 (14.2–65.7)
HCV treatment history
Treatment-naı¨ve 411 (68) 262 (88) 673 (75)
Treatment-experiencedb 191 (32) 35 (12) 226 (25)
Baseline HCV RNA level, median (range), log10 IU/mL 6.2 (1.2–7.6) 6.6 (0.7–7.6) 6.3 (0.7–7.6)
FIB-4 index, median (range) 1.4 (0.3–7.8) 1.5 (0.3–7.9) 1.4 (0.3–7.9)
FIB-4 index
\ 1.45 317 (53) 147 (49) 464 (52)
1.45–3.25 244 (41) 122 (41) 366 (41)
[ 3.25 41 (7) 28 (9) 69 (8)
IL28B
CC 217 (36) 165 (56) 382 (42)
Non-CC 385 (64) 132 (44) 517 (58)
Presence of key baseline substitutions, n (%)
NS3 onlyc 9 (2) 2 (\ 1) 11 (1)
NS5A onlyd 81 (14) 26 (9) 107 (13)
NS3 ? NS5Ac,d 1 (\ 1) 1 (\ 1) 2 (\ 1)
Baseline NS5A Y93H, n (%) 54 (9) 0 54 (6)
History of disorders, n (%)
Hypertension 153 (25) 42 (14) 195 (22)
Gastroesophageal reflux disease 45 (7) 7 (2) 52 (6)
Hyperlipidemia 13 (2) 14 (5) 27 (3)
Diabetes 41 (7) 20 (7) 61 (7)
Cardiovascular disease 187 (31) 108 (36) 295 (33)
Chronic kidney disease stage 4 or 5e 3 (\ 1) 7 (2) 10 (1)
Concomitant medications, n (%)
Calcium channel blockers 77 (13) 46 (15) 123 (14)
Angiotensin II receptor blockers 67 (11) 23 (8) 90 (10)
Statins 32 (5) 17 (6) 49 (5)
Proton pump inhibitors 53 (9) 37 (12) 90 (10)
BMI body-mass index, HCV hepatitis C virus, FIB-4 fibrosis-4
aIncludes 132 GT1-infected and 104 GT2-infected Japanese patients from CERTAIN-1 and CERTAIN-2 Phase 3 clinical trials
bPrior treatment experience with interferon (IFN)/pegIFN ± ribavirin (RBV)
cDefined as having any baseline NS3 resistance-associated variant (at amino acid positions 155, 156, and 168) at C 15% NGS detection threshold
dDefined as having any baseline NS5A resistance-associated variant (at amino acid positions 24 (GT2 only), 28, 30, 31 (GT1 only), 92 (GT2
only), and 93) at C 15% NGS detection threshold
eDefined as estimated glomerular filtration rate (eGFR)\ 30 mL/min/1.73 m2 at screening
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SVR Sustained virologic response
DAA Direct acting antiviral
JSH Japan Society of Hepatology
G/P Glecaprevir/pibrentasvir
RAS Resistance-associated substitution
CKD Chronic kidney disease
IFN Interferon
RBV Ribavirin
AST Aspartate aminotransferase
APRI Aspartate aminotransferase–platelet ratio index
SVR12 Sustained virologic response at post-treatment
week 12
ITT Intent-to-treat
FIB-4 Fibrosis-4
AE Adverse event
ALT Alanine aminotransferase
Introduction
Chronic hepatitis C virus (HCV) infection affects 71 mil-
lion individuals worldwide including approximately 1.5
million in Japan [1, 2]. Genotypes (GT) 1 and 2 comprise
approximately 55% of all HCV infection globally,
including [ 97% of all HCV infections in Japan [3, 4].
Patients with chronic HCV infection commonly have
comorbidities and use co-medications, particularly elderly
patients who constitute a large portion of the HCV-infected
patient population in Japan [5]. Untreated patients with
chronic HCV infection are at risk for fibrosis progression,
cirrhosis, and hepatocellular carcinoma (HCC), especially
elderly patients who have a greater prevalence of advanced
fibrosis [6–8]. Achievement of sustained virologic response
(SVR) has been shown to improve liver function and
decrease risk of liver-related and all-cause mortality
[9, 10].
Despite the advent of safe and effective direct-acting
antivirals (DAA) for treating chronic HCV infection, there
was still a need for simplified treatment regimens suit-
able for shorter treatment durations in patients regardless of
baseline viral or patient characteristics. Prior to 2017,
treatment guidelines in the United States of America,
Europe, and Japan recommended treatment durations of
12 weeks or more for most approved HCV regimens in
DAA-naı¨ve patients without cirrhosis [11–13]. Shorter
treatment durations could improve patient adherence since,
amongst patients with HCV, adherence has been shown to
decrease over the course of 12-week treatment [14]. Both
previous and current guidelines also recommend assessing
for comorbidities and co-medication use prior to treatment
initiation due to the potential for drug–drug interactions
that may impact treatment response [11–13, 15–17]. Lastly,
prior to 2017, no pangenotypic DAA regimen was
approved in Japan. Thus, there was an unmet need, espe-
cially in Japan, for a shorter duration and pangenotypic
regimen that is highly efficacious regardless of baseline
viral or patient characteristics.
The DAA combination of glecaprevir (NS3/4A protease
inhibitor developed by AbbVie and Enanta) and pibren-
tasvir (NS5A inhibitor), co-formulated as the once-daily,
pangenotypic regimen of glecaprevir/pibrentasvir (G/P),
was recently approved for patients with chronic HCV GT1-
6 infection including those with compensated cirrhosis,
chronic kidney disease (CKD), and prior DAA failure in
Japan and overseas. In vitro, both glecaprevir and pibren-
tasvir exhibit a high barrier to resistance, since they retain
their nanomolar and picomolar potencies, respectively,
against resistance-associated substitutions (RASs) includ-
ing the NS5A RASs Y93H and L31M/V [18–20]. In its
overseas clinical trials conducted outside of Japan, 8- and
12-week treatment in patients without cirrhosis and with
HCV genotypes 1–6 achieved similarly high (C 95%)
SVR12 rates [21]. Integrated analyses across these patients
also confirmed that there was no significant difference in
SVR12 rates between the 8- and 12-week durations for any
of the baseline characteristics analyzed including fibrosis
stage and the presence of baseline polymorphisms in NS3
or NS5A [21]. In 2 separate active-controlled clinical trials
conducted in Japan, 8-week G/P treatment demonstrated
non-inferiority to previous standards of care for DAA-
naı¨ve Japanese patients without cirrhosis and with GT1 or
GT2 infection [22, 23], leading to the recommendation for
8-week treatment in these patients regardless of baseline
viral or patient characteristics [17].
Here, we present an integrated analysis of the six
overseas and Japan-only Phase 2/3 clinical trials that
evaluated 8-week G/P treatment in order to summarize the
safety and efficacy of 8-week G/P treatment and to assess
its efficacy by baseline patient and disease characteristics.
Methods
Analysis set
This is an integrated analysis of data from the six Phase 2
and 3 clinical trials that assessed the efficacy and safety of
8 weeks of glecaprevir and pibrentasvir in treatment-naı¨ve
or pegIFN/RBV-experienced patients without cirrhosis and
with HCV GT1 or GT2 infection. Patients received gle-
caprevir 300 mg and pibrentasvir 120 mg co-administered
(Phase 2) or co-formulated G/P (300 mg/120 mg; Phase 3)
dosed orally as a three-pill, once-daily regimen taken with
food for 8 weeks. All patients provided written informed
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consent. Studies were designed and conducted in accor-
dance with the Good Clinical Practice guidelines, Decla-
ration of Helsinki, and applicable local regulation, with
approval from independent ethics committees or institu-
tional review boards at all study sites. The detailed
methodology and primary outcomes have been published
previously for all studies (CERTAIN-1 [NCT02707952],
CERTAIN-2 [NCT02723084], SURVEYOR-I
[NCT02243280], SURVEYOR-II [NCT02243293],
ENDURANCE-1 [NCT02604017], and EXPEDITION-2
[NCT02738138]) [22–27]. All authors had access to data
from this integrated analysis, and reviewed and approved
the final manuscript for submission.
Patients
Patients with GT1 or GT2 infection were at least 18 years
of age and positive for anti-HCV antibody with a plasma
HCV RNA viral load C 10000 IU/mL in Phase 2 or
C 1000 IU/mL in Phase 3 at the Screening Visit. Eligi-
bility for 8-week treatment required that patients were
without cirrhosis, and were either HCV treatment-naı¨ve or
had prior treatment experience with interferon (IFN)/
pegIFN ± ribavirin (RBV). The absence of cirrhosis was
defined using a hierarchal approach in all studies, where
sites utilized liver biopsy, transient elastography, or
screening Fibrotest and aspartate aminotransferase (AST)–
platelet ratio index (APRI) as outlined in the Supporting
Information. In CERTAIN-1 and -2 only, the absence of
cirrhosis could also be confirmed by a Screening Dis-
criminant Score (z)\ 0 as outlined in the Supporting
Information.
Assessments
HCV genotype was determined using the Versant HCV
Genotype Inno LiPA Assay, Version 2.0 or higher (LiPA;
Siemens Healthcare Diagnostics, Tarrytown, NY), and
confirmed by phylogenetic analysis of viral sequences.
Baseline viral load and SVR12 were assessed using PCR to
quantify plasma HCV RNA; assay details are described in
the Supporting Information. Patients with key baseline
substitutions were classified as anyone with a resistance-
associated variant in NS3 (at amino acid positions 155,
156, and 168) or NS5A (at amino acid positions 24 (GT2
only), 28, 30, 31 (GT1 only), 92 (GT2 only), and 93).
Safety was evaluated through physical examinations,
laboratory testing, and monitoring of adverse events. Non-
serious and serious AEs were monitored throughout G/P
treatment until 30 days post-treatment and up to 24 weeks
post-treatment, respectively. Treatment-emergent adverse
events (TEAEs) were defined as any AE with an onset date
after the first G/P dose and no more than 30 days after the
last G/P dose. All AEs were coded using the Medical
Dictionary for Regulatory Activities (MedDRA) version
20.0 and were assessed for their relationship to G/P by
study investigators.
Endpoints
The primary endpoint was the rate of sustained virologic
response (HCV RNA\ lower limit of quantification) at
12 weeks post-treatment (SVR12) for both Japanese and
overseas patients by genotype. Secondary endpoints
included the number of on-treatment virologic failures and
relapses. Subgroup analyses further evaluated overall
SVR12 rates by baseline patient and disease characteristics
including presence of advanced fibrosis, comorbidities, and
co-medication use. The presence of advanced fibrosis was
assessed using the FIB-4 index that is a validated, non-
invasive method with high specificity ([ 97%) for identi-
fying patients with advanced fibrosis (F3/F4) using[ 3.25
as a cut-off and high negative predictive value ([ 90%) for
excluding advanced fibrosis using a cut-off of \ 1.45
compared to liver biopsy [28, 29]. Safety was evaluated in
both Japanese and overseas patients by assessing the
number and percentage of patients with treatment-emer-
gent adverse events and laboratory abnormalities.
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Fig. 1 Overall SVR12 comparing Japan and overseas rates by
genotype. Efficacy of 8-week G/P treatment defined as SVR12 is
reported for both Japan and overseas patients by genotype using an
ITT analysis. The table lists the reason for non-response including
virologic (breakthrough or relapse) and non-virologic failure (prema-
ture discontinuation or missing SVR12) for each group. Premature
d/c, Premature discontinuation
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Fig. 2 SVR12 by baseline
patient and disease
characteristics. Efficacy of
8-week G/P treatment reported
by baseline patient (a) and
disease (b) characteristics using
an ITT analysis. The dashed line
represents the overall SVR12
for 899 patients included in the
analysis. aAll patients with
missing data for baseline
polymorphisms achieved
SVR12. bDefined as having any
baseline NS3 resistance-
associated variant (at amino
acid positions 155, 156, and
168) at C 15% NGS detection
threshold. cDefined as having
any baseline NS5A resistance-
associated variant (at amino
acid positions 24, 28, 30, 92,
and 93) at C 15% NGS
detection threshold
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Statistical analyses
In this retrospective analysis of data from phase 2 and 3
clinical trials, efficacy and safety analyses were performed
for the intention-to-treat (ITT) population that included all
patients assigned to 8-week G/P (300/120 mg) treatment
who received C 1 dose of G/P. The number and percentage
of patients in this ITT population achieving SVR12 for
each genotype and overall were summarized with two-
sided 95% confidence intervals calculated using the Wilson
score method.
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Fig. 3 SVR12 by comorbidities
and co-medications. Efficacy of
8-week G/P treatment, defined
as SVR12, is reported by
comorbidity (a–b) and co-
medications (c) using an ITT
analysis. GERD,
gastroesophageal reflux disease;
CKD, chronic kidney disease;
CCB calcium channel blockers,
ARB angiotensin receptor
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inhibitors
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Results
Baseline patient demographics and characteristics
This analysis included 899 patients with chronic hepatitis C
genotypes 1–2 from six Phase 2 and 3 clinical trials who
were treated with G/P for 8 weeks. Among these 899
patients, 602 (67%) and 297 (33%) patients were chroni-
cally infected with HCV genotype 1 and 2, respectively.
Most patients (n, %) were either white (555, 62%) or Asian
(287, 31%), treatment-naı¨ve (673, 75%), and\ 65 years of
age (725, 81%); the median FIB-4 index was 1.4. The
analysis population included 69 (8%) patients with
advanced fibrosis as defined by FIB-4 [ 3.25 as well as
295 (33%) patients with cardiovascular disease and 90
(10%) taking proton pump inhibitors. Table 1 describes
full patient characteristics both overall and by HCV
genotype.
Efficacy outcomes
Overall, the rate of SVR12 by ITT analysis was 98.9%
(889/899; 95% CI = 98.0–99.4) with numerically compa-
rable SVR12 rates between Japan and overseas patients
with HCV GT1 (Japan: 99.2%, 131/132, 95% CI =
95.8–99.9; overseas: 99.1%, 466/470, 95% CI =
97.8–99.7) and GT2 infection (Japan: 97.9%, 95/97, 95%
CI = 92.8–99.4; overseas: 98.5%, 197/200, 95% CI =
95.7–99.5) (Fig. 1). Of the 10 patients who did not achieve
SVR12, no Japanese patients and only 2 (\ 1%) patients
overall experienced virologic failure, including one on-
treatment virologic failure and one relapse. One overseas
patient with GT1a infection and prior pegIFN/RBV treat-
ment experienced on-treatment virologic failure by treat-
ment day 49, leading to premature discontinuation of G/P.
One overseas patient with GT2a infection and prior
pegIFN/RBV treatment had relapse by post-treatment week
12. More information on the virologic failures is included
in Table S1.
Rates of SVR12 by ITT analysis were[ 98% regardless
of baseline variables including gender, race, age, body-
mass index (BMI), prior HCV treatment history, FIB-4
index, and viral load (Fig. 2). All patients with baseline
NS3 or NS5A polymorphisms in key resistance-associated
variants including 54 patients with the NS5A Y93H RAS
achieved SVR12. Notably, SVR12 was achieved at
numerically comparable rates between patients with more
advanced fibrosis (FIB-4[ 3.25; 98.6%) and those without
advanced fibrosis (FIB-4\ 1.45; 98.9%).
SVR12 rates by ITT analysis remained [ 97% for
patients with common comorbidities and co-medications
(Fig. 3). SVR12 rates were numerically comparable for
patients with or without the corresponding comorbidities
(Fig. 3a), CKD stages 1/2 or 3/4/5 (Fig. 3b), and con-
comitant medications (Fig. 3c), respectively. Of note, all
10 Japanese patients with chronic kidney disease (CKD)
stage 4 or 5 achieved SVR12.
Table 2 Adverse events in
Japanese and overseas patients
Event Japan GT1-2
N = 229
Overseas GT1-2
N = 670
Overall
N = 899
Any AE, n (%) 125 (55) 416 (62) 541 (60)
Any DAA-relateda AE 50 (22) 234 (35) 284 (32)
Any serious AE 3 (1) 11 (2) 14 (2)
Any DAA-relateda serious AEs 0 0 0
Any AE leading to study drug discontinuation 1 (\ 1) 1 (\ 1) 2 (\ 1)
Any AE leading to study drug interruption 0 1 (\ 1) 1 (\ 1)
Common AEs (occurring in C 5% of patients)
Headache 13 (6) 99 (15) 112 (12)
Fatigue 1 (\ 1) 80 (12) 81 (9)
Viral upper respiratory tract infectionb 28 (12) 35 (5) 63 (7)
Nausea 8 (3) 53 (8) 61 (7)
Deaths 0 1 (\ 1)c 1 (\ 1)c
AE adverse event, DAA direct acting antiviral
aDAA relatedness determined by study investigator
bAdverse events of common cold included per MedDRA version 20.0 that were previously coded as
nasopharyngitis in MedDRA version 19.0
cOverseas patient died from adenocarcinoma attributed to enlarge peripancreatic nodes and determined to
be not related to G/P
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Safety outcomes
Overall, 541 of 899 (60%) patients reported C 1 treatment-
emergent adverse event (AE) including 125 of 229 (55%)
Japanese patients and 416 of 670 (62%) patients from
overseas (Table 2), of which most Japanese (94%;
118/125) and most overseas (96%; 400/416) patients
experienced an AE with a maximum severity of mild
(Grade 1) or moderate (Grade 2). Overall, the most com-
mon AEs occurring in C 5% of patients were headache
(12%), fatigue (9%), viral upper respiratory tract infection
(7%), and nausea (7%). Headache and fatigue appeared to
be reported less frequently in Japanese patients than in
those from overseas (6% compared to 15% for headache
and \ 1% compared to 12% for fatigue); however, there
was a higher rate of viral upper respiratory tract infections
in Japanese patients compared to those from overseas (12%
compared with 5%, respectively). Serious AEs were
reported in 14 (2%) patients occurring at similar rates
between Japanese (1%) and overseas (2%) patients; none
were considered related to G/P by the study investigator.
Two (\ 1%) patients prematurely discontinued G/P due to
AEs. One patient from overseas discontinued study drug
due to a serious AE of adenocarcinoma on treatment day 29
and subsequently died 60 days post-treatment as a result of
this serious AE; this was considered not related to G/P.
A Japanese patient experienced non-serious AEs of nausea
and vomiting related to G/P that led to treatment discon-
tinuation on day 18.
Grade C 3 laboratory abnormalities were rare with no
Japanese patients experiencing grade C 3 laboratory
abnormalities in hemoglobin, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), or total bilirubin.
Overall, no grade C 3 laboratory abnormalities occurred in
hemoglobin or ALT levels. One overseas patient had a
Grade 3 AST elevation on Day 41 that returned within
normal limits by Day 49. Three overseas (\ 1%) patients
had Grade 3 elevations in total bilirubin, which were not
accompanied by concurrent ALT elevation. There were no
events consistent with hepatic decompensation or drug-
induced liver injury.
Discussion
Overall, 8-week G/P treatment was highly efficacious in
DAA-naı¨ve patients without cirrhosis and with HCV GT1
or GT2 infection regardless of baseline patient and disease
characteristics assessed. Efficacy of 8-week G/P treatment
was not impacted by previous predictors of non-response
for other DAA regimens including advanced fibrosis,
consistent with previous findings from an overseas analysis
of G/P [21]. Furthermore, common comorbidities and co-
medications in Japan did not impact efficacy of G/P [5].
Overall, this analysis strengthens the evidence from the
Japan-only studies, CERTAIN-1 and -2, further supporting
8-week G/P treatment in DAA-naı¨ve patients without cir-
rhosis and with GT1 or GT2 infection by increasing the
sample size in subpopulations of interests, including
patients with advanced fibrosis and other common
comorbidities. Altogether, in older patient populations
particularly those in Japan, United States, and Italy that
more commonly present with advanced fibrosis, comor-
bidities, and co-medication use [5, 6], G/P offers a highly
efficacious 8-week treatment option for DAA-naı¨ve
patients without cirrhosis and with GT1-2 infection
regardless of baseline patient or disease characteristics.
In both Japanese and overseas patients, 8-week G/P
treatment was well tolerated with low rates of AEs leading
to study drug discontinuation, serious AEs, and laboratory
abnormalities including no Grade C 3 ALT elevations.
Historically, patients with chronic HCV infection, partic-
ularly the elderly, experienced high discontinuations rates
with IFN-based regimens [30]; however, IFN-free DAA
regimens are safe and well tolerated in all patients,
including the elderly, with low rates of AEs leading to
study drug discontinuation, serious AEs, and laboratory
abnormalities [31, 32]. In both the overseas and Japan-only
trials, G/P treatment had infrequent (\ 1%) rates of dis-
continuations due to AEs, DAA-related serious AEs, and
grade 3 or higher laboratory abnormalities even in older
patients or those treated with G/P for longer durations
[22, 23, 33, 34]. In particular, unlike some first-generation
protease inhibitor-containing regimens, Grade C 3 ALT
elevations were rare (\ 1%) and there were no instances
consistent with drug-induced liver injury or hepatotoxicity
across G/P’s overseas and Japan-only registrational pro-
grams [32]. Dedicated clinical trials also previously
demonstrated that G/P is safe and well tolerated in a broad
range of patients eligible for 8-week G/P treatment
including those with CKD stages 4 or 5 and human
immunodeficiency virus [25, 35]. In particular, G/P was
well tolerated in both overseas and Japanese patients with
CKD stages 3, 4, or 5 due to a low rate of AEs leading to
discontinuation and no DAA-related serious AEs along
with a safety profile consistent with pre-existing comor-
bidities in the CKD population [35–39]. The higher rates of
upper respiratory tract infection in Japanese patients are
consistent with high reported rates of this AE (10–35%)
observed in Japan-only clinical trials from other DAA
regimens [40–42]. Taken together with its efficacy data,
8-week G/P treatment is a safe and efficacious regimen for
DAA-naı¨ve patients without cirrhosis from Japan or
overseas.
There are limitations to this integrated analysis inherent
to its design. There are a low number of patients in some
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subgroups specifically patients with any NS3 polymor-
phism, with chronic kidney disease stage 4 or 5, or with a
race other than White, Black, or Asian. Patients eligible for
8 week treatment in the real world may be more hetero-
geneous than this clinical trial population, including
patients with underrepresented comorbidities in this anal-
ysis. An ongoing Phase 3b clinical trial (EXPEDITION-5)
reported that G/P was highly efficacious and well tolerated
in patients with HCV GT1-4 infection and CKD stage 3b to
5, including a 96% SVR12 rate and no virologic failures in
84 treatment-naı¨ve or pegIFN/RBV-experienced patients
without cirrhosis treated for 8 weeks with G/P [37].
Overall, 8-week G/P treatment is highly efficacious and
safe in patients without cirrhosis and with HCV genotype 1
or 2 infection. These data support the current JSH recom-
mendation for 8-week G/P treatment in DAA-naı¨ve
patients without cirrhosis and with HCV genotype 1 or 2
infection regardless of baseline patient or viral character-
istics [17].
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